These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
165 related items for PubMed ID: 20013687
1. [Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option]. Serra AL, Wüthrich RP. Praxis (Bern 1994); 2009 Dec 16; 98(25):1511-6. PubMed ID: 20013687 [Abstract] [Full Text] [Related]
15. Sirolimus therapy to halt the progression of ADPKD. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, Ondei P, Rubis N, Diadei O, Gherardi G, Prandini S, Panozo A, Bravo RF, Carminati S, De Leon FR, Gaspari F, Cortinovis M, Motterlini N, Ene-Iordache B, Remuzzi A, Remuzzi G. J Am Soc Nephrol; 2010 Jun 26; 21(6):1031-40. PubMed ID: 20466742 [Abstract] [Full Text] [Related]
16. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. Tao Y, Kim J, Schrier RW, Edelstein CL. J Am Soc Nephrol; 2005 Jan 26; 16(1):46-51. PubMed ID: 15563559 [Abstract] [Full Text] [Related]
17. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? Canaud G, Knebelmann B, Harris PC, Vrtovsnik F, Correas JM, Pallet N, Heyer CM, Letavernier E, Bienaimé F, Thervet E, Martinez F, Terzi F, Legendre C. Am J Transplant; 2010 Jul 26; 10(7):1701-6. PubMed ID: 20642692 [Abstract] [Full Text] [Related]
18. Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis. Xue C, Dai B, Mei C. Nephron Clin Pract; 2013 Jul 26; 124(1-2):10-6. PubMed ID: 24022660 [Abstract] [Full Text] [Related]